Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451859 | 0.88 | ADORA2A (0.70) | ADORA2AADORA1 | |
| SCHEMBL5466593 | 0.87 | ADORA2A (0.81) | ADORA2AADORA1ADORA3ADORA2BYTHDC1 | |
| SCHEMBL5461148 | 0.86 | ADORA2A (0.56) | ADORA2AADORA1 | |
| SCHEMBL5466032 | 0.83 | ADORA2A (0.74) | ADORA2AADORA1ADORA3ADORA2BYTHDC1 | |
| SCHEMBL3268539 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL5466465 | 0.82 | ADORA2A (0.56) | ADORA2AADORA1SLC29A1 | |
| SCHEMBL5454720 | 0.82 | ADORA2A (0.59) | ADORA2AADORA1 | |
| SCHEMBL5456489 | 0.82 | ADORA2A (0.62) | ADORA2AADORA1 | |
| SCHEMBL5461300 | 0.82 | ADORA2A (0.56) | ADORA2AADORA1 | |
| SCHEMBL5467475 | 0.81 | ADORA2A (0.57) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452894-B2 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-11-18 | — | — | US | disclosed |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | OPRL1, CNR1, CNR2 | ADORA2A 13/4885ADORA1 28/4885ADORA3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.